Array Biopharma to Present Clinical Data on ARRY-520, a KSP Inhibitor, and ARRY-614, a Dual p38/Tie2 Inhibitor, at the 201

BOULDER, Colo.--(BUSINESS WIRE)-- Array BioPharma Inc. (NASDAQ: ARRY) today announced data will be presented on two drug candidates, ARRY-520, a KSP inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the 2011 Annual Meeting of the American Society of Hematology in San Diego, California.

The abstracts can be accessed through the American Society of Hematology website, www.hematology.org/Meetings/Annual-Meeting. The abstract titles are provided below; however, please note that according to ASH press policies, all data are embargoed until the time of the beginning of the presentation. After the presentations, the posters and presentation slides will be available as PDFs on Array's website at www.arraybiopharma.com.

Poster:

   

ARRY-520 Shows Durable Responses in Patients with Relapsed/Refractory Multiple Myeloma in a Phase 1 Dose-Escalation Study  (Publication #1860)

Date:

Saturday, December 10, 2011

Time:

5:30–7:30 p.m. PST

Location:

San Diego Convention Center, Hall GH
 

Oral

Presentation:

Phase 1 Dose-Escalation/Expansion Study of the p38/Tie2 Inhibitor ARRY-614 in Patients with IPSS Low/Int-1 Risk Myelodysplastic Syndromes (Abstract #118)

Presenter:

Rami S. Komrokji, M.D., Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute

Date:

Sunday, December 11, 2011

Time:

5:15 p.m. PST

Location:

San Diego Convention Center, Room 6CF
 

Poster:

The Novel KSP Inhibitor ARRY-520 Demonstrates Single-Agent Activity in Refractory Myeloma: Results From a Phase 2 Trial in Patients with Relapsed/Refractory Multiple Myeloma (MM) (Publication #2935)

Date:

Sunday, December 11, 2011

Time:

6–8 p.m. PST

Location:

San Diego Convention Center, Hall GH
 

About Array BioPharma

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small-molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target proteins and are aimed at significant unmet medical needs. For more information on Array, please go to www.arraybiopharma.com.



CONTACT:

Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
[email protected]

KEYWORDS:   United States  North America  California  Colorado

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.